Lisa Bennett, MD
Ophthalmology · Mequon, WINPI 1619354743
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,619 of the $6,925 with a category attached, or 66.7%. 25 manufacturers reported payments, led by Biotissue Holdings Inc. at 24.6% of the total. Reporting peaked in 2019 at $2,524 and has fallen 82.1% since, to $453 in 2025. Among ophthalmology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $51.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$2K
- Johnson & Johnson Surgical Vision, Inc.$989
- Glaukos Corporation$943
- NEW World Medical,inc.$927
- Bausch & Lomb Americas Inc.$407
- AbbVie$354
- plus $2K from 19 others
What the payments were for
- Consulting fees$69010%
- Travel & lodging$1,56123%
- Food & beverage$4,61967%
- Education$180%
- Gifts$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 19 | $1,705 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $989 |
| Glaukos Corporation | 7 | $943 |
| NEW World Medical,inc. | 24 | $927 |
| Bausch & Lomb Americas Inc. | 10 | $407 |
| AbbVie(2 entities) | 12 | $354 |
| Alcon | 8 | $311 |
| Tarsus Pharmaceuticals, Inc. | 4 | $177 |
| Harrow Eye, LLC | 4 | $169 |
| Oyster Point Pharma, Inc. | 6 | $156 |
| Novartis | 8 | $148 |
| Sun Pharmaceutical Industries Inc. | 3 | $144 |
| Astellas Pharma US Inc | 1 | $88 |
| Amgen | 3 | $65 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $63 |
| Dompe US, Inc. | 2 | $51 |
| Rxsight Inc | 2 | $42 |
| Sight Sciences, Inc. | 3 | $41 |
| The Cameron-ehlen Group, Inc. | 2 | $32 |
| Rayner Intraocular Lenses Limited | 1 | $24 |
| Thea Pharma Inc. | 1 | $20 |
| Omeros Corporation | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Ivantis, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$1,411
- AmnioGraft$1,411
- AmnioGuard$1,255
- Tecnis 1-piece IOL$730
- Tecnis Multifocal Family of 1-piece IOLS$730
- Tecnis Symfony IOL$730
- Kahook Dual Blade$456
- Clearpath$456
- Ahmed Glaucoma Valve$456
- Streamline$456
- MIEBO$159
- XIIDRA$159
- VYZULTA$159
- iStent Trabecular Micro-Bypass System Model iS3$158
- Hydrus Microstent$147
- XEN$124
- XDEMVY$115
- CEQUA$114
- VEVYE$100
How this compares
$6,925 in reported general payments places this provider in the 90th percentile of 337 ophthalmology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 86 | $91,337 |
| XiidraLifitegrast | 46 | $49,168 |
| XdemvyLotilaner | 15 | $27,899 |
| Cyclosporine | 30 | $12,661 |
| Latanoprost | 749 | $7,413 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $2,413 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 178 | $2,073 |
| Prednisolone Acetate | 66 | $1,936 |
| Timolol Maleate | 258 | $1,645 |
| Brimonidine Tartrate | 169 | $1,364 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 18 | $708 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 55 | $623 |
| Ketorolac Tromethamine | 11 | $505 |
| ErythromycinErythromycin Base | 33 | $420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $354 | $91,33786 claims |
| Bausch & Lomb Americas Inc.Xiidra | $407 | $49,16846 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $177 | $27,89915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 337 ophthalmology providers in Wisconsin.
Other ophthalmology in Mequon
- Inder SinghRacine$2.5M
- Deepak SambharaWausau$388K
- John VukichWauwatosa$356K
- Eugene EldridgeKenosha$294K
- Michael ShapiroMadison$71K
- Douglas SalmAppleton$38K
- Julia AgapovMadison$26K
- Thomas HarveyChippewa Falls$23K
- Michael VrabecAppleton$20K
- Philip SmithMinocqua$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.